SA
GILD icon

Sovran Advisors’s Gilead Sciences GILD Stock Holding History

Sovran Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
8,475
+632
+8% +$83.3K 0.08% 240
2026
Q1 		$1.03M Buy
7,843
+1,115
+17% +$156K 0.08% 243
2025
Q4 		$816K Buy
6,728
+830
+14% +$101K 0.07% 263
2025
Q3 		$699K Sell
5,898
-447
-7% -$50.8K 0.06% 274
2025
Q2 		$705K Sell
6,345
-493
-7% -$52.5K 0.07% 258
2025
Q1 		$715K Buy
6,838
+1,278
+23% +$132K 0.09% 224
2024
Q4 		$506K Buy
+5,560
New +$501K 0.07% 254

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sovran Advisors's GILD Position: Q2 2026 in Review

Sovran Advisors increased its Gilead Sciences (GILD) stake by 8.1% in Q2 2026, buying an estimated $83.3K and bringing the position to 8,475 shares worth $1.14M. The position accounts for 0.08% of the portfolio, ranked #240.

Sovran Advisors first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. 2,274 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Sovran Advisors held 8,475 shares of Gilead Sciences worth $1.14M as of Q2 2026.
  • Sovran Advisors bought 632 Gilead Sciences shares in Q2 2026, an estimated $83.3K.
  • Gilead Sciences made up 0.08% of Sovran Advisors's portfolio in Q2 2026, its #240 holding.
  • Sovran Advisors first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • 2,274 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.